Q-omics provides the consensus-scored CSNK1A1P3 profile across patient tissues and cancer cell-line models. CSNK1A1P3 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CSNK1A1P3 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, CSNK1A1P3 RNA expression shows 6,047 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LUSC, and STAD as cancer lineages where CSNK1A1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK1A1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK1A1P3 survival associations across molecular data types. CSNK1A1P3 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK1A1P3 RNA expression–survival associations across cancer types. High CSNK1A1P3 expression shows unfavorable associations in MESO, ACC, COAD, KICH and READ, but favorable associations in LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for CSNK1A1P3 RNA expression.
This table summarizes CSNK1A1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSNK1A1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK1A1P3 shows lower tumor expression in LUSC. The LUSC box plot shows higher CSNK1A1P3 RNA expression in normal versus tumor tissue (log2 FC = −0.048, t-test p = .033).
This table shows molecular features associated with CSNK1A1P3 in patient tissues and cancer cell lines. In patient samples, CSNK1A1P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
